Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · IEX Real-Time Price · USD
1.310
-0.020 (-1.50%)
At close: May 17, 2024, 4:00 PM
1.370
+0.060 (4.58%)
After-hours: May 17, 2024, 5:46 PM EDT

Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.

The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.

It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.

The company is based in Houston, Texas.

Nexalin Technology, Inc.
Nexalin Technology logo
Country United States
Founded 2010
IPO Date Sep 16, 2022
Industry Medical Devices
Sector Healthcare
Employees 6
CEO Mark White

Contact Details

Address:
1776 Yorktown, Suite 550
Houston, Texas 77056
United States
Phone (832) 260-0222
Website nexalin.com

Stock Details

Ticker Symbol NXL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.15
CIK Code 0001527352
CUSIP Number 65345B201
ISIN Number US65345B2016
Employer ID 27-5566468
SIC Code 3845

Key Executives

Name Position
Marilyn Elson Controller
Mark White President, Chief Executive Officer, Chief Financial Officer and Director
John Patrick Claude Co-Founder and Director of Engineering and Development
Dr. David Owens M.D. Chief Medical Officer and Director
Michael Nketiah Senior Vice-President of Quality, Regulatory and Clinical Affairs

Latest SEC Filings

Date Type Title
May 14, 2024 RW Filing
May 10, 2024 10-Q Quarterly Report
Apr 26, 2024 8-K Current Report
Apr 16, 2024 S-3 Registration statement under Securities Act of 1933
Apr 11, 2024 8-K Current Report
Mar 27, 2024 10-K Annual Report
Mar 20, 2024 8-K Current Report
Jan 17, 2024 DEF 14A Other definitive proxy statements
Nov 13, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report